(2018) could identify significant differences in HLA class I profiles when comparing AML patients with NPM1 mutation and healthy individuals who indirectly support the hypothesis that T-cell-mediated immune responses contribute to disease control in patients with NPM1 mutations (23). Here, NPM1 is linked to acute myeloid leukemia.